SLSNasdaqPharmaceutical PreparationsUS GAAP · USD

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics. Its pipeline includes galinpepimut-S (GPS), a WT1-targeted peptide immunotherapy, and SLS009 (tambiciclib), a selective CDK9 inhibitor, with development activities centered on hematologic malignancies and solid tumors.

Kysy yhtiöstä
Liikevoitto (EBIT)−28,3milj. USD
+10,3 %v/v
Nettotulos−26,9milj. USD
+13,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−50−40−30−20−10010milj. USD2020: 1,9 milj. USD2020: EBIT −17 milj. USD20202021: 7,6 milj. USD2021: EBIT −25 milj. USD20212022: 1,0 milj. USD2022: EBIT −42 milj. USD20222023: 0,00 milj. USD2023: EBIT −38 milj. USD20232024: EBIT −32 milj. USD20242025: EBIT −28 milj. USD2025−28
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Lead oncology immunotherapy50 %

GPS is a WT1-directed peptide immunotherapy being developed for multiple cancer indications.

Small-molecule oncology therapy35 %

SLS009 is a selective CDK9 inhibitor being developed as a cancer therapeutic.

Clinical-stage development programs10 %

Research and clinical trial activities supporting pipeline advancement and regulatory preparation.

Licensing and collaboration revenue5 %

Revenue from out-licensing or partnering arrangements such as the 3D Medicines Agreement.

Asiakkaat

SELLAS does not sell commercial medicines; its direct counterparties are typically pharmaceutical partners, research collaborators, and licensing counterparties. The eventual end users of its therapies would be oncology patients treated through hospitals, cancer centers, and specialist physicians if products are approved.

Pharmaceutical licensing partners

Buy or license development and commercialization rights to oncology assets such as GPS or SLS009.

Clinical trial sites and investigators

Run the company’s studies and generate the data needed for regulatory filings and partnering.

Oncology patients and treating physicians

Future end users of approved therapies in AML, blood cancers, and solid tumors.

Regional biotech and pharma collaborators

Potential partners for territory-specific licensing, co-development, or marketing rights.

Strategia

SELLAS is focused on advancing its clinical-stage oncology pipeline toward regulatory milestones and potential partnering opportunities. The company’s strategy relies on generating clinical data for GPS and SLS009, while using licensing and collaboration agreements to support development and eventual commercialization.

Complete late-stage development of GPSLyhyt aikaväli

Clinical data are needed to support a BLA and potential commercialization.

Advance SLS009 developmentKeskipitkä aikaväli

Diversifies the pipeline and creates a second oncology asset for partnering or development.

Secure strategic collaborations and licensing dealsKeskipitkä aikaväli

Partnerships can provide non-dilutive funding and commercialization reach.

Preserve financing flexibilityLyhyt aikaväli

Clinical-stage biotech requires ongoing capital to fund trials and operations.

Maantiede

SELLAS is headquartered in the United States and conducts its development and corporate activities from there. Its pipeline is intended for global oncology markets, and the company has referenced discussions with global and regional pharmaceutical companies for licensing and co-development.

Riskit

SELLAS faces the typical risks of a clinical-stage oncology company: trial failure, regulatory delays, and uncertainty around whether its assets will achieve approval or market adoption. It also depends on external financing and partnering to fund development, which can be dilutive or unavailable on acceptable terms.

Järjestetty vakavuuden mukaan
Clinical development failureKriittinen

GPS and SLS009 are still in development, so efficacy or safety results may not support approval.

KohdistuuGPSSLS009REGAL study
Financing and dilution riskKorkea

The company has historically funded operations through equity and convertible instruments.

KohdistuuPublic and private financingsWarrant exercises
Regulatory and approval riskKorkea

Oncology products require successful clinical and regulatory review before commercialization.

Kohdistuu: BLA preparation and FDA review

Partnering and commercialization riskKeskitaso

Future funding and market access may depend on licensing or co-development agreements.

Kohdistuu: Global and regional pharma collaborations

Competitive oncology landscapeKeskitaso

Competing therapies may limit trial enrollment, pricing power, or eventual uptake.

Kohdistuu: AML and broader cancer indications

Kirjanpito

Harkinnanvaraiset erät
Licensing revenue recognition

Revenue has been limited to the 3D Medicines Agreement, so contract timing and milestones can drive reported revenue.

Vaikutus: Can create uneven revenue recognition across periods

Clinical trial cost expensing

Most development spending is expensed as incurred, making R&D the main operating cost.

Vaikutus: Directly affects operating loss and period comparability

Equity financing and warrant accounting

Registered direct offerings and warrant exercises are a major source of liquidity and can affect share count.

Vaikutus: Impacts cash, equity, and dilution

Going-concern and liquidity assessment

Future operations depend on additional financing and successful development progress.

Vaikutus: Important for assessing financial statement assumptions

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Seres Therapeutics, Inc.

MCRB · Pharmaceutical Preparations

Terns Pharmaceuticals, Inc.

Pharmaceutical Preparations

GENELUX Corp

GNLX · Pharmaceutical Preparations

Silexion Therapeutics Corp

SLXNW · Biological Products, (No Diagnostic Substances)

Erasca, Inc.

ERAS · Pharmaceutical Preparations

Apollomics Inc.

APLMW · Pharmaceutical Preparations

Päivitetty: 24.9.2026